mavrilimumab
Selected indexed studies
- Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. (Ann Rheum Dis, 2022) [PMID:35264321]
- Mavrilimumab for severe COVID-19. (Lancet Rheumatol, 2020) [PMID:33521661]
- Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. (Expert Opin Investig Drugs, 2019) [PMID:31208237]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. (2022) pubmed
- Mavrilimumab for severe COVID-19. (2020) pubmed
- Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. (2019) pubmed
- Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review. (2021) pubmed
- Mavrilimumab for severe COVID-19. (2020) pubmed
- Safety and Efficacy of Mavrilimumab For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. (2021) pubmed
- Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. (2017) pubmed
- Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis. (2014) pubmed
- Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy. (2012) pubmed
- Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab. (2018) pubmed